BioCardia (NASDAQ:BCDA) Stock Rating Upgraded by Zacks Research

BioCardia (NASDAQ:BCDA) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

BCDA has been the topic of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a report on Friday, July 17th. Wall Street Zen upgraded BioCardia to a “sell” rating in a report on Saturday, July 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research report on Tuesday, June 9th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $25.00.

BioCardia Trading Down 5.6%

Shares of NASDAQ BCDA opened at $0.88 on Tuesday. BioCardia has a 12-month low of $0.75 and a 12-month high of $2.29. The company has a market cap of $10.01 million, a P/E ratio of -0.97 and a beta of 0.48. The stock has a fifty day moving average price of $0.94 and a 200 day moving average price of $1.08.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. On average, sell-side analysts forecast that BioCardia will post -0.76 EPS for the current fiscal year.

Insider Buying and Selling at BioCardia

In other BioCardia news, Director Simon H. Stertzer bought 39,000 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were acquired at an average cost of $1.00 per share, with a total value of $39,000.00. Following the completion of the transaction, the director owned 166,338 shares in the company, valued at $166,338. The trade was a 30.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 145,900 shares of company stock worth $137,212 in the last three months. 17.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. DRW Securities LLC acquired a new stake in BioCardia during the 4th quarter valued at approximately $72,000. Geode Capital Management LLC raised its position in shares of BioCardia by 70.4% in the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new position in shares of BioCardia during the 2nd quarter valued at approximately $40,000. Hedge funds and other institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.